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ABSTRACT 
The cost-effectiveness of testing for multiple genes implicated in adverse drug reactions requires the 
simultaneous assessment of all actionable information, including future prescribing decisions based 
on incidental findings. We developed methodology for determining the value of pharmacogenetic 
panel tests, illustrated with a multi-gene panel including HLA-A*31:01, HLA-B*15:02, HLA-B*57:01, 
HLA-B*58:01, HLA-B (158T) and HLA-DQB1 (126Q). If the findings for all alleles are acted upon, 
regardless of their individual cost-effectiveness, the HLA panel resulted in cost savings of £378 
(US$491), and a QALY gain of 0.0069. Based on a stratified analysis and compared with no testing, 
initial use of the panel was cost-effective in patients eligible for abacavir (HLA-B*57:01), 
carbamazepine (HLA-A*31:01) and clozapine (HLA-B (158T) and HLA-DQB1 (126Q)) but not for 
carbamazepine (HLA-B*15:02) or allopurinol (HLA-B*58:01). The methods presented allow for the 
assessment of the cost-effectiveness of multiple-gene panels. 
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INTRODUCTION 
Pharmacogenomic-based personalised medicine holds the promise of optimising prescribing 
decisions by improving the targeting of treatment or reducing the likelihood of adverse drug 
reactions (ADRs), which are among the leading causes of iatrogenic morbidity and mortality [1].  In 
this context, genotyping can be used predictively in order to prevent ADRs by taking precautionary 
action such as excluding certain drugs, reducing the dose, or by providing increased monitoring to 
high-risk groups [2]. Pharmacogenetic information may also be used pre-emptively, that is, to inform 
a current prescribing decision based on stored data from previous genetic testing [3]; to inform 
practice for monitoring, and to assist with clinical diagnosis following a suspected ADR [2]. 
More than 10% of drug labels in the USA and EU contain information on genetic factors determining 
drug response, although only a minority of these have been implemented in current practice. This is 
mainly because of a lack of evidence on the clinical effectiveness and utility of testing, but also 
because of potential concerns about their cost-effectiveness [4]. As few as one in ten drugs with FDA 
labels which include genetic information have associated economic data [5], and of these only a 
minority are considered to be cost effective [6, 7]. The need for economic evidence will become 
more pressing, given the risk of the rapid pace of knowledge and technological advancements in 
genomics resulting in untested innovations being adopted as routine without evidence of cost-
effectiveness [8]. 
It is acknowledged that the health technology assessment of diagnostic and prognostic tests is 
complex, but analytical frameworks have been developed [9]. Methods for assessing the cost-
effectiveness of single-gene pharmacogenetic tests are well described [7, 10, 11], as are the 
challenges, which often include a lack of robust data, uncertainties around downstream costs and 
benefits, and the sensitivity of the results to key modelling assumptions [12, 13]. The advent of 
multi-gene panel testing and whole genome sequencing will require that multiple genes are 
assessed simultaneously, greatly enhancing the usefulness of testing, but also further increasing the 
complexity of assessing value. 
Conceptually, a cost-effectiveness analysis of a multi-gene panel would necessitate a separate 
economic analysis of every informative result, each weighted to determine the overall cost-
effectiveness. However, this poses significant challenges in terms of data requirements, modelling 
complexity and analytical approach. Assessing the value of a panel of pharmacogenes linked to ADRs 
to treatments for HIV, diabetes, hypertension and asthma, for instance, would become infeasible 
given the requirement to model the costs and outcomes for each disease. Some commentators have 
proposed a welfarist approach to the economic evaluation of genetic testing [14], given that 
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difficult-to-quantify benefits may be derived from predictive, diagnostic or prognostic information as 
well as potential improvements in health. 
Many applications of next-generation sequencing panels consider a single disease such as a 
particular cancer, focus on diagnosis and risk to family members [15, 16], or guided treatment [15, 
17], where models and outcomes focus on a single decision at a single point in time. Newborn 
screening panels consider a wider range conditions, but economic analyses often focus on the most 
prevalent or life-limiting outcome [18]. A review of cost-effectiveness of whole genome sequencing 
and whole exome sequencing noted that there were very few full economic evaluations, and indeed 
there was a paucity of robust evidence to inform economic evaluations [19]. A single study has been 
identified which considers the cost-effectiveness of pharmacogenetic panel testing, using a discrete 
event simulation model [20]. While this approach offers a flexible solution to assessing the cost-
effectiveness of a small genetic panel test, it is not readily extensible to larger panels due to 
computational complexity and extensive data requirements.  
The present study aims to formalise an alternative framework for assessing the cost-effectiveness of 
pharmacogenetic tests used in different clinical contexts of ADR management; and to introduce 
methodology for the efficient determination of the cost-effectiveness of a panel of multiple genes 
associated with ADRs. 
 
RESULTS 
Cost-effectiveness of a pre-specified 2-gene panel 
A scenario of sequential testing, where a patient with epilepsy and eligible for carbamazepine is 
tested for HLA-A*31:01 and who later develops gout and is eligible for allopurinol (and tested for 
HLA-B*58:01) is presented in Figure 1a. Compared with the standard practice of not testing, the 
reported incremental, total cost of genotyping for HLA-A*31:01 alone is £300, inclusive of a test cost 
of £54 [21]. The incremental cost excluding the cost of testing (δCost) is £268 once inflated to 2017 
GBP [22], and the incremental quality-adjusted life year (QALY) is 0.0234 [21]. Following the same 
approach for HLA-B*58:01, the incremental cost, excluding that of the test, is £49, and incremental 
QALYs 0.0023 [23]. Gout has an estimated incidence of 1.77 per 1000 person-years, with 27.3% of 
patients receiving urate lowering therapy within 12 months of diagnosis [24]. Of these, 89% are 
anticipated to receive allopurinol [25], resulting in 0.43 incident prescriptions of allopurinol per 1000 
person-years. 
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Assuming each test costs £50 (US$65), the incremental costs and QALYs of testing for both genes 
sequentially are £319 and 0.0234, respectively, resulting in an ICER of £13,611 (US$17,695) per QALY 
gained (Box 1). 
Box 1: Incremental cost and QALY of sequential testing for HLA-A*31:01 and HLA-B*58:01 
Based on Equation 1 ΔCostA*31:01 Sequence = (£50+£268) + 0.00043 * (£50+£49) = £319 
Based on Equation 2 ΔQALYA*31:01 Sequence = 0.0234 + 0.00043*0.0023 = 0.0234 
Based on Equation 3 ICERA*31:01 Sequence = £319 / 0.0234 = £13,611 per QALY gained 
The inclusion of both genes in a single panel benefits from generating incidental findings at zero 
marginal cost. Box 2 presents a panel result depending on presenting condition, where results of 
incidental findings are considered exclusive of test cost (Figure 1b). Based on a panel test cost of 
£50, the incremental cost of testing for HLA-A*31:01 inclusive of incidental findings for HLA-B*58:01 
is £318, and with a corresponding incremental QALY of 0.0234, resulting in an ICER of £13,610 
(US$17,694) per QALY gained. The reverse sequence, with HLA-A*31:01 as an incidental finding, is 
estimated to cost £99 and generate 0.0023 additional QALYs, resulting in an ICER of £43,205 
(US$56,167) per QALY gained. This is based on 0.08 incident carbamazepine prescriptions per 1000 
person-years, derived from the incidence of epilepsy, estimated at 0.51 per 1000 population per 
year [26], and the proportion of patients estimated to be prescribed carbamazepine (10%-20%) 
[Personal communication, Prof AG Marson, 26th February 2018, Dr G Powell 27th February 2018]. 
Box 2: Incremental cost and QALY of testing inclusive of incidental findings 
Based on Equation 4:  ΔCost+A*31:01 = £50 + £268 + 0.00043*£49 = £318 
   ΔCost+B*58:01 = £50 + £49 + 0.00008*£268 = £99 
Based on Equation 5:  ΔQALY+A*31:01 = 0.0234 + 0.00043*0.0023 = 0.0234 
 ΔQALY+ B*58:01 = 0.0023 + 0.00008*0.0234 = 0.0023 
Based on Equation 6:  ICER+A*31:01 = £318/0.0234 = £13,610 per QALY gained 
  ICER+B*58:01 = £99/0.0023 = £43,205 per QALY gained 
The cost-effectiveness of the panel, independent of presenting condition (Figure 1c), is calculated by 
weighting incremental costs and QALYs by the likelihood of testing for each allele which can be 
estimated from the relative proportions of incident allopurinol and carbamazepine prescriptions 
(Box 3). The contribution of HLA-A*31:01 as the predictive test is calculated as 15% of predictive 
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tests, and the contribution of HLA-B*58:01 is 85% of predictive tests. Overall costs and QALYs of the 
panel, compared with standard care of no testing are £133 and 0.0055, respectively, resulting in a 
panel ICER of £24,148 (US$31,393) per QALY gained. 
Box 3: Incremental cost and QALY of panel testing 
Based on Equation 7:  Weightcarbamazepine = 0.00008/(0.00008+0.00043) = 0.15 
   Weightallopurinol = 0.00043/(0.00008+0.00043) = 0.85 
Based on Equation 8:  ΔCostPanel = 0.15*£318 + 0.85*£99 = £133 
Based on Equation 9: ΔQALYPanel = 0.15*0.0023 + 0.85*0.0234 = 0.0055 
Based on Equation 10:  ICERPanel = £133/0.0055 = £24,148 per QALY gained 
Whilst on average, the overall panel cost effectiveness of £24,148 per QALY gained is acceptable at a 
threshold of £30,000 per QALY, testing predictively when a patient presents with gout is not cost-
effective. However, acting on information on HLA-B*58:01 is cost-effective as an incidental finding of 
a panel ordered for patients eligible for carbamazepine (δCost/ΔQALY = £21,491 (US$27,938) per 
QALY gained). The optimised use of the panel costs £13,610 (US$17,694) per QALY gained, equal to 
that of testing for HLA-A*31:01, inclusive of incidental findings.  The improvement in cost-effective 
compared with sequential testing is enhanced when considering multiple genes.    
Cost-effectiveness of a specified multi-gene HLA panel 
The cost effectiveness of a £50 multi-gene panel for HLA-A*31:01, HLA-B*15:02, HLA-B*57:01, HLA-
B*58:01, HLA-B (158T) and HLA-DQB1 (126Q), dependent on the initial predictive test, is presented 
in Table 1. For a patient with epilepsy and eligible for carbamazepine or phenytoin (with the 
incidental findings for all other HLA-alleles), the panel had an ICER of £15,638 (US$20,330) per QALY 
gained and would be considered cost-effective with a probability of 0.75 at a threshold of £30,000 
per QALY. The panel would also be considered to be cost-effective for a patient with HIV eligible for 
abacavir, or a patient with treatment-resistant schizophrenia eligible for clozapine, both at a 
probability of 1.0. However, based on a patient presenting with gout, an initial panel test request for 
HLA-B*58:01 (with incidental findings for all other HLA-alleles) had an ICER of £43,038 (US$55,950) 
per QALY gained, and a probability of 0.26 of being cost-effective at £30,000 per QALY. 
In the case that the panel was to be implemented such that all findings are acted upon (where 
applicable) regardless of cost-effectiveness, the panel resulted in a cost saving of £378 (US$491) and 
0.0069 QALYs gained, therefore dominating standard care (Table 2). The probability of cost-
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effectiveness at the £30,000 per QALY threshold was 1.0 indicating that this panel configuration is 
cost-effective, and should be adopted into routine practice. 
Cost-effectiveness of an optimized multi-gene panel 
In the context of designing an optimal panel to maximise cost-effectiveness for the National Health 
Service (NHS) in the UK, testing for HLA-B*15:02 is not cost-effective, even as an incidental find 
(incremental net monetary benefit, INMB -£36; -US$47) and is consequently removed from the 
panel. Testing for HLA-B*58:01 is only cost-effective as an incidental find, and is therefore not 
included as a predictive test within the overall panel result (INMB -£30; -US$40). In this 
configuration, the panel results in a cost saving of £1,388 (US$1,805) and a QALY gain of 0.0163. 
Both the pre-specified and optimised panels are viable, (i.e. the probability of the panel being cost-
effective for initial use in at least two conditions was 1.0) which in a policy context suggests multi-
gene testing to be more appropriate than single-gene testing.  
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DISCUSSION 
This study introduces methods for determining the economic value of panel-based genotyping to 
diagnose, predict, exclude, monitor and pre-empt adverse drug reactions. The case study illustrated 
how the cost-effectiveness of a panel depends critically on the cost-effectiveness of incidental 
findings, the likelihood of future exposure to other pharmacogenetic drugs, the context of the initial 
request for the test, as well as the effectiveness and downstream costs of testing. In the case of 
acting on the main or incidental findings of a £50 multi-gene panel test for HLA-A*31:01, HLA-
B*15:02, HLA-B*57:01, HLA-B*58:01, HLA-B (158T) and HLA-DQB1 (126Q), the panel is both cost 
saving and more effective, than standard care. However, cost-effectiveness can be further improved 
by removing HLA-B*15:02, and not using the panel as a predictive test in patients presenting with 
gout who are eligible for allopurinol. 
The analysis is novel in that it allows for the assessment of cost utility of multi-gene testing in 
different contexts, across a variety of conditions, through all incidental findings. Veenstra, (2016) 
[27] proposed generalised estimates of incremental clinical benefit, derived by improving drug 
effectiveness or avoiding harm, and incremental costs saved (or spent) as a result of modifying drug 
therapy and avoiding adverse outcomes, in the context of warfarin pharmacogenetic screening. The 
analysis is limited by having no derivation of how these can be calculated more specifically – e.g. 
relating to positive predictive value (PPV), negative predictive value (NPV), cost or benefit of 
avoiding specific ADR; restricted to a 2-gene panel (CYP2C9 and VKOR variants); considered 
immediately relevant information (and so no weighting for incidental findings); and defined 
incremental cost in terms of an overall screening panel, rather than on presentation of condition. A 
discrete event simulation model applied previously in the context of a multigene panel, is limited by 
computational requirements, which can restrict their applicability to a small number of risk genes 
[20]. Moreover, they do not overcome the problem of needing to model each and every disease 
impacted by the use of testing. Our frameworks for estimating the cost-effectiveness of single-gene 
tests, whilst simplified from a full model, have the strength of using lifetime data reflecting 
downstream costs and consequences.  
There are a number of key assumptions, however, which also limit our analysis. We assume 
independence of conditions and allele prevalence and we assume that drug prescriptions are 
independent and that there is no cross-reactivity between drugs. These factors could conceivably be 
incorporated into the analysis, provided the necessary information is available for simulation. The 
case study may be limited by heterogeneity, in that the ICERs for each single gene test are 
conducted on disparate populations.  
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In conclusion, this study has presented methodology which can be used to assess the potential 
future costs and benefits of multi-gene panels. Whilst the specific context is prevention of adverse 
drug reactions, this framework may be adapted for economic evaluation of multi-gene panels for 
other applications.  
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METHODS 
A framework for assessing the economic value of multi-gene panel testing was developed to 
estimate the cost-effectiveness of a pre-specified panel, assuming action upon test results for all 
future relevant prescription decisions; and to design a cost-effective panel through selection of 
appropriate genes for action predictively and within incidental findings (this is equivalent to 
specifying how best to utilise an existing panel). Both approaches are presented in the context of 
diagnosing, predicting, excluding, monitoring and pre-empting adverse drug reactions [2]. The 
methods are introduced by describing each step in relation to a 2-gene panel. A case study of a 
multi-gene panel test is then developed to illustrate the practical application of the methods. 
To improve modelling efficiency, two analytic approaches are proposed: One based on evidence 
available from existing economic evaluations of single gene tests, and the other, for situations where 
such evidence does not exist, based on economic evaluations of the drugs causing the ADRs in 
question. 
Estimating the cost-effectiveness of a pre-specified 2-gene panel 
In the context of a single gene test, the incremental cost (ΔCost) is the sum of the test cost (CostPGx) 
and the cost of acting upon the results (such as in relation to prescribing alternative doses or 
medicines), (δCost). The incremental cost-effectiveness ratio is ΔCost divided by the incremental 
QALY (ΔQALY). If two single gene tests are used in sequence, the overall cost-effectiveness (versus a 
strategy of not testing) is a function of CostPGx, δCost and ΔQALYs associated with each test, and the 
likelihood of patients requiring the second test. Figure 1a presents a schematic representation of 
testing for HLA-A*31:01 and HLA-B*58:01 in sequence for predicting severe ADRs to carbamazepine 
and allopurinol, with calculations for cost-effectiveness of this scenario presented below. 
Equation 1 ΔCostA*31:01 Sequence = (CostPGx + δCostA*31:01)+ Incidenceallopurinol Rx* (CostPGx + δCostB*58:01) 
Equation 2 ΔQALYA*31:01 Sequence = ΔQALYA*31:01+ Incidenceallopurinol Rx* ΔQALYB*58:01 
Equation 3 ICERA*31:01 Sequence = ΔCostA*31:01 Sequence / ΔQALYA*31:01 Sequence 
If both genes were included in a single panel, information on the second allele is incidental to the 
principal findings (Figure 1b). Assuming the panel unit cost includes all aspects of testing (including 
for instance, quality control, relevant aspects of clinical decision support systems and electronic 
health records), incidental findings are available at zero marginal cost.  In this context, the 
incremental costs (ΔCost+A*31:01) and QALYs (ΔQALY+A*31:01) of testing for HLA-A*31:01 predictively, 
inclusive of incidental findings (denoted by +) can be modelled according to:  
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Equation 4 ΔCost+A*31:01 = CostPanel + δCostA*31:01+ Incidenceallopurinol Rx*δCostB*58:01 
Equation 5 ΔQALY+A*31:01 = ΔQALYA*31:01+ Incidenceallopurinol Rx*ΔQALYB*58:01  
Equation 6 ICER+A*31:01 = ΔCost+A*31:01 / ΔQALY+A*31:01 
For a patient who presents initially with gout, who later has a possibility of developing epilepsy, an 
ICER can similarly be derived for testing for HLA-B*58:01 inclusive of incidental findings for HLA-
A*31:01 by substituting HLA-A*31:01 for HLA-B*58:01 in the above equations.  
Costs and QALYs for the panel, independent of presenting condition, are a composite of both 
possible predictive tests, where the contribution of each starting point is based on the relative 
likelihood of testing for HLA-A*31:01 before HLA-B*58:01 (or vice versa): 
Equation 7 Weight carbamazepine = Incidencecarbamazepine Rx / (Incidencecarbamazepine Rx + Incidenceallopurinol Rx) 
Equation 8 ΔCostPanel = Weight A*31:01 * ΔCost+A*31:01 + Weight B*58:01 * ΔCost+B*58:01  
Equation 9 ΔQALYPanel = Weight A*31:01 * ΔQALY+A*31:01 + Weight B*58:01 * ΔQALY+B*58:01  
Equation 10 ICERPanel = ΔCostPanel / ΔQALYPanel 
Estimating the cost-effectiveness of a multi-gene HLA panel 
The methods for extending and generalizing beyond a 2-gene panel, to a multi-gene panel, are 
presented in the Supplementary Appendix. These are illustrated with a more comprehensive HLA 
gene panel for preventing ADRs. Additional cost-utility analyses for HLA-B*15:02 [28], HLA-B*57:01 
[29], and HLA-B (158T) and HLA-DQB1 (126Q) [30] were identified from a purposive search of the 
literature. In this illustrative example, we relaxed assumptions of cost perspective and healthcare 
setting. 
The incremental cost (exclusive of the test cost, δCosts) associated with a strategy of testing 
compared with standard care, and associated differences in ΔQALYs were extracted for analysis. 
Costs were converted to GBP [31], and then inflated to 2017 values using the hospital and 
community health services index [22]. The main results are presented also in US dollars, using a 
currency exchange rate of $1.30 to the pound. 
All inputs into the economic model of the multi-gene panel are summarised in Table 3. Analyses 
were conducted based on a panel costing £50 to estimate the ICER of the panel by assuming all 
results are acted upon, where applicable; and in the context of designing a cost-effective panel, 
based on a cost-effectiveness threshold of £30,000 per QALY (λ) [35]. Parameter uncertainty was 
considered using Monte-Carlo simulation, drawing from the distributions of the input parameters, to 
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generate 95% central ranges (CR) for the incremental costs and QALYs, and to calculate the 
likelihood of each single gene test being included as a predictive test, or within the incidental 
findings. 
Designing an optimized multi-gene panel 
An efficient panel test can be designed by including tests for genes which are cost-effective 
individually (within incidental findings), or in combination (as a predictive test inclusive of incidental 
findings). This is achieved by imposing the following conditions: 
i) In order to exclude tests which are not cost-effective within the incidental findings, a 
threshold is applied on the INMB for incidental findings. Genes are only included on the 
panel if IMNB = λ*ΔQALY – δCost ≥ 0 
ii) In order to exclude tests which are not cost-effective predictively (inclusive of incidental 
findings), in the final panel calculations (Equations 5 and 6), only predictive tests where 
iii) A multi-gene test is then defined as being viable, over and above a single gene test, 
when there are at least two combinations of drug-allele and indication, for which 
INMB+ ≥ 0. Based on simulation, using a series of Monte Carlo replications, the 
likelihood of a test being viable is defined as the proportion of replications in which 
multiple INMB+ ≥ 0 
Methods for approximating incremental costs and QALYs for single gene tests 
Where published single gene economic evaluations cannot be identified, or cannot be practicably 
performed (e.g. because of the number and complexity of considering multiple genes or drugs), then 
approximation of cost-effectiveness is required. This concept has been discussed previously in terms 
of the costs saved and benefits gained through pharmacogenetic testing [27]. Here, we propose 
further methods to estimate values of ΔCost, δCost, and ΔQALY using existing evidence on the costs 
and QALYs of both treatment, and the ADR avoided. These are dependent on the context of testing 
[2]. 
Predicting adverse drug reactions 
Genotyping can be used predictively to inform a specific prescribing decision (pre-prescription 
genotyping). This might determine whether a patient is at an increased risk of experiencing an ADR, 
and provide information on whether an alternative drug is indicated or whether a dose reduction is 
warranted. Patients with the HLA-B*57:01 allele, for instance, must avoid abacavir and be prescribed 
an alternative anti-retroviral drug for their HIV infection as they would otherwise be at 15-fold 
higher risk of experiencing a hypersensitivity reaction compared with the general population [36].  
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Information on variant CYP2C9 or VKORC1 alleles can be used to guide warfarin dose, to reduce the 
risk of haemorrhagic events, and maintain effective anticoagulation [37]. 
Assuming that there is an appropriate alternative treatment (or dose) that is associated with no risk 
of the same ADR, the incremental costs and QALYs of genotyping may be readily estimated. Most 
ADRs occur soon after treatment commencement, and so the consequences of their avoidance are 
captured by the short term cost savings and QALYs gained. As cost-effectiveness relies on 
incremental costs and QALYs, only differences between strategies, highlighted in Figure 2, are 
considered in the final derivation (see Supplementary Appendix).  
For chronic treatments (Figure 2a), the long term costs and consequences (including harms) are 
captured in the incremental costs (ΔCostalternative) and QALYs (ΔQALYalternative), relative to the 
alternative drug (or dose) indicated by the test result or prescribed for patients who experience an 
ADR. These can be derived from relevant published economic evaluations. 
Based on these, the incremental costs of a single-gene test can be approximated by sum of the cost 
of testing; the incremental cost of the alternative weighted by the probability of being prescribed 
the alternative; less the cost of ADR avoided (weighted by the likelihood of ADR) 
Equation 11:  
ΔCost
=  CostPGx
+ 𝑃(allele) ∗ (1 − PPV) ∗ ΔCostalternative
− 𝑃(allele) ∗ PPV ∗ CostADR 
and the corresponding incremental QALY, by the sum of the incremental QALY of the alternative 
weighted by the probability of being prescribed the alternative, and the QALYs gained through 
avoiding the ADR  
Equation 12:  
ΔQALY
=  𝑃(allele) ∗ (1 − PPV) ∗ ΔQALYalternative
− 𝑃(allele) ∗ PPV ∗  QALYADR 
where, P(allele) is the probability of the presence of the risk allele, and PPV is the positive predictive 
value of the test, that is, the probability of a patient experiencing the ADR if they test positive for the 
allele. CostADR is the cost of treating the ADR, and QALYADR is a QALY decrement associated with 
the ADR. 
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For cases where there does not exist an alternative drug (or dose) with a negligible risk of the same 
ADR (Figure 2b), then incremental costs and QALYs of prescribing an alternative drug (where the 
ADR is not mediated by the same allele) can be calculated as: 
Equation 13:  
ΔCost
=  CostPGx
+ 𝑃(allele) ∗ (1 − PPV) ∗ ΔCostalternative
− 𝑃(allele) ∗ (PPV + PPV ∗ 𝑃(ADR)alternative − 𝑃(ADR)alternative) ∗  CostADR 
Equation 14:  
ΔQALY
=  𝑃(allele) ∗ (1 − PPV) ∗ ΔQALYalternative
− 𝑃(allele) ∗ (PPV + PPV ∗ 𝑃(ADR)alternative − 𝑃(ADR)alternative) ∗  QALYADR 
Costs and QALYs associated with a second ADR are considered additively; however it is assumed that 
in the event of an ADR with the alternative drug (or dose), then a further alternative has the same 
costs and QALYs as the alternative, but no further risk of ADR. 
In cases where the ADR is associated with non-negligible mortality (Figure 2c), 
Equation 15:  
ΔCost =  CostPGx
+ 𝑃(allele) ∗ (1 − PPV) ∗ ΔCostalternative
+ 𝑃(allele) ∗ PPV ∗ 𝑃(mort) ∗ Costalternative
− 𝑃(allele) ∗ PPV ∗ CostADR 
Equation 16:  
ΔQALY
=  𝑃(allele) ∗ (1 − PPV) ∗ ΔQALYalternative
+ 𝑃(allele) ∗ PPV ∗ 𝑃(mort) ∗ QALYalternative
− 𝑃(allele) ∗ PPV ∗  QALYADR 
where, Costalternative and QALYalternative are the costs and QALYs associated with using the 
alternative drug, and P(mort) is the probability of not surviving the ADR. 
Treatments indicated for acute conditions require additional considerations (Figure 2d).  Existing 
economic evaluations are likely to be limited in having a short time horizon, whereas patients might 
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be exposed to treatment (and risk of ADR) on any number of future occasions. In this case, the long 
term consequences of a change in regimen are multiplied by the anticipated future number of 
prescriptions of the drug over a patient’s lifetime, Nfuture: 
Equation 17:  
ΔCost
=  CostPGx
+ 𝑃(allele) ∗ (1 − PPV) ∗ ΔCostalternative ∗ 𝑁future
− 𝑃(allele) ∗ PPV ∗ CostADR 
Equation 18:  
ΔQALY
=  𝑃(allele) ∗ (1 − PPV) ∗ ΔQALYalternative ∗ 𝑁future
− 𝑃(allele) ∗ PPV ∗ QALYADR 
Pre-empting adverse drug reactions 
Once information on a patient’s genotype is already known (either due to a panel test, whole 
genome sequence, or a prior single-gene test which is relevant to more than one drug), the 
information may be used to guide a patient’s future drug therapy (incidental findings) [2]. As with 
the case of prediction, the information may be used to exclude a drug from the regimen of high risk 
patients, reduce the dose, or implement a risk-based adjustment of their monitoring programme. 
Incremental costs (denoted as 𝛿Cost) can be approximated in the same way as for the case of 
prediction, but with the omission of test cost, as this represents a sunk cost following the initial test. 
Equation 19:  
𝛿Cost = ΔCost − CostPGx 
The QALYs associated with pre-empting ADRs in this way, are calculated as for prediction. 
Monitoring adverse drug reactions 
Where there are no alternative treatments (such as for patients requiring clozapine for treatment-
resistant schizophrenia, but who are also carriers of HLA-DQB1) [38], or where the genetic risk factor 
may predispose to both mild and serious ADRs (e.g. HLA-A*31:01 and carbamazepine) [39], 
pharmacogenetic information may be used to implement a monitoring programme that stratifies 
patients based on their risk of ADR [2]. The monitoring of high risk patients may be more frequent or 
16 
 
intensive compared with that of low-risk patients, who may receive less monitoring and experience 
no increased risk of ADR. 
The economic analysis of monitoring is not as straightforward as for prediction (Figure 2e), as the 
proportion of patients who change treatment may not be the same as the proportion of ADRs 
reduced, and the cost of monitoring may be attributed to a change in either or both high (increased 
monitoring) and low (decreased monitoring) risk patients. The model therefore applies adjustments 
(based on a priori assumptions) to the above formulae, based on the proportions of ADR reduction 
and regimen change as a result of monitoring. 
Equation 20:  
ΔCost
=  CostPGx
+ P(allele) ∗ CostMonitor
+ 𝑃(allele) ∗ 𝑃(regimen change) ∗ ΔCostalternative
− 𝑃(allele) ∗ PPV ∗ 𝑃(ADR reduction) ∗ CostADR 
Equation 21:  
ΔQALY
=  𝑃(allele) ∗ 𝑃(regimen change) ∗ ΔQALYalternative
− 𝑃(allele) ∗ PPV ∗ 𝑃(ADR reduction) ∗ QALYADR 
Diagnosis of adverse drug reactions 
Diagnostic pharmacogenetic testing has clinical utility in distinguishing the cause of a disease (Figure 
2f). For instance, if a patient with gallstones were to present with jaundice, but who was also taking 
flucloxacillin, a negative test for HLA-B*57:01 could exclude flucloxacillin as being the cause of the 
jaundice [2, 40]. Without correct determination of causality, flucloxacillin might have been stopped 
inappropriately, and the patient would be noted as being allergic to flucloxacillin, and prescribed 
alternative (and potentially more expensive and less effective) antibiotics in the future. The 
downstream benefits of diagnostic pharmacogenetic testing would include avoidance of alternate 
antibiotics, reduced need for further diagnostic testing and potential impacts on antimicrobial 
resistance. 
In the context of diagnosis and tests with high NPV, the presence of an allele would suggest the drug 
as the cause, and the patient would be prescribed alternatives in future. A negative test result would 
exclude the drug as being the cause of the symptoms, and the patient may continue their prescribed 
medication. In standard care, further diagnostic testing may be required to establish causality. 
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The incremental costs of using genetic testing for diagnosis can be approximated as: 
Equation 22:  
ΔCost
=  CostPGx
− (1 − 𝑃(allele)) ∗ ΔCostalternative ∗ 𝑁future
− 𝑃(allele) ∗ Costdiagnosis 
The corresponding incremental QALYs can be approximated as: 
Equation 23:  
ΔQALY
=  −(1 − 𝑃(allele)) ∗ ΔQALYalternative ∗ 𝑁future 
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STUDY HIGHLIGHTS 
What is the current knowledge on the topic? 
Demonstration of cost-effectiveness is a barrier to the broader adoption and implementation of 
pharmacogenetic testing in routine practice. 
What question did the study address? 
How can the cost-effectiveness of multi-gene panels for avoiding adverse drug reactions be 
assessed, and how can a cost-effective panel be designed? 
What does this study add to our knowledge?  
Methods are developed which allow for the cost-effectiveness assessment of multi-gene panels, and 
which consider the multitude of affected drugs, clinical indications and prescribing decisions. This is 
illustrated with a case study of a multi-gene HLA panel. 
How might this change clinical pharmacology or translational science?   
As multi-gene panel testing and whole genome sequencing become credible alternatives to single 
gene tests, assessment of their cost-effectiveness is particularly relevant given that the availability of 
additional genetic information could impact on any number of future prescribing decisions.  
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Figure 1: Illustration of (a) single gene testing, including the option of sequential testing; (b) 
incidental findings; and (c) panel testing for the 2-gene case study. 
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Figure 2: Schematic representation of decision trees illustrating (a) the use of an alternative treatment (or dose) associated with no ADR; (b) the use of 
an alternative treatment (or dose) which is associated with an ADR that is not mediated by the same allele; (c) the incorporation of mortality effects 
associated with the ADR; (d) the use of testing in the context of acute treatments; (e) the use of testing where change in monitoring is warranted; and 
(f) the use of pharmacogenetic testing for diagnostic purposes. 
In incremental analysis, between strategies of testing and not testing, the darker shaded branches of the decision trees cancel. 
NPV: Negative Predictive Value; PPV: Positive Predictive Value; P: probability; ADR: Adverse Drug Reaction 
*Pragmatically, Alternative2 assumed to have same costs and QALYs as first alternative, but zero risk of ADR 
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Table 1: Multi-gene panel test result, dependent on presenting indication 
Allele 
Drug 
Condition 
Cost-effectiveness of single gene 
test costing £0 (incidental finding) 
Cost-effectiveness of single gene 
test costing £50 
Cost-effectiveness of pre-specified 
panel costing £50 
(by presenting condition) 
Cost-effectiveness of optimised 
panel costing £50 
(by presenting condition) 
HLA-A*31:01 
Carbamazepine 
Epilepsy 
1. £268 
2. 0.0234 
3. £11,473/QALY 
4. INMB: £434 
5. 80% 
1. £318 
2. 0.0234 
3. £13,610/QALY 
4. INMB: £384 
1. £378 
2. 0.0242 
3. £15,638/QALY 
4. INMB: £348 
5. 75% 
1. £318 
2. 0.0234 
3. £13,596/QALY 
4. INMB: £384 
5. 77% 
HLA-B*15:02 
Carbamazepine & 
phenytoin 
Epilepsy 
1. £60 
2. 0.0008 
3. £75,391/QALY 
4. INMB: -£36 
5. 0% 
1. £110 
2. 0.0008 
3. £137,891/QALY 
4. INMB: -£86 
Excluded from optimised panel - 
not cost effective, even as 
incidental finding 
HLA-B*57:01 
Abacavir 
HIV 
1. -£3,148 
2. 0.0170 
3. Dominant* 
4. INMB: £3,658 
5. 100% 
1. -£3,098 
2. 0.0170 
3. Dominant* 
4. INMB: £3,608 
1. -£3,098 
2. 0.0170 
3. Dominant* 
4. INMB: 3,608 
5. 100% 
1. -£3,098 
2. 0.0170 
3. Dominant* 
4. INMB: £3,608 
5. 100% 
HLA-B*58:01 
Allopurinol 
Gout 
1. £49 
2. 0.0023 
3. £21,491/QALY 
4. INMB: £20 
5. 65% 
1. £99 
2. 0.0023 
3. £43,230/QALY 
4. INMB: -£30 
1. £99 
2. 0.0023 
3. £43,038/QALY 
4. INMB: -£30 
5. 26% 
1. £99 
2. 0.023 
3. £43,037/QALY 
4. INMB: -£30 
5. 26% 
HLA-B & HLA-DQB1 
Clozapine 
Schizophrenia 
1. -£623 
2. -0.0003 
3. £2,273,246/QALY‡ 
4. INMB: £615 
5. 100% 
1. -£573 
2. -0.0003 
3. £2,090,746/QALY‡ 
4. INMB: £565 
1. -£573 
2. -0.0003 
3. £2,126,100/QALY‡ 
4. INMB £565 
5. 100% 
1. -£573 
2. -0.0003 
3. £2,117,942/QALY‡ 
4. INMB: £565 
5. 100% 
 
1. Incremental cost versus no testing 
2. Incremental QALYs versus no testing 
3. Incremental cost-effectiveness ratio versus no testing 
4. Incremental net monetary benefit (INMB), based on a threshold of £30,000 per QALY 
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5. Likelihood of cost-effectiveness at a threshold of £30,000 per QALY 
*South-east quadrant of the cost-effectiveness plane – dominant means less costly and more effective than not testing 
‡South-west quadrant of the cost-effectiveness plane – less costly and less effective than not testing (cost-effective if >£30,000 per QALY) 
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Table 2: Multi-gene panel test result, independent of presenting indication 
Scenario Test cost Panel cost 
(95% CR) 
Panel QALY 
(95% CR) 
Panel ICER  
(% viable simulations*) 
Implementation 
Cost-effectiveness of pre-specified 
panel 
£50 
-£378 
(-£472, -£284) 
0.0069 
(0.0023, 0.0117) 
Dominant 
N/A 
Dominant at £30,000 per QALY: 
All results assumed to be actioned 
Optimising the cost-effectiveness 
of the panel (based on £30,000 per 
QALY threshold) 
£50 
-£1,388 
(-£2619, -£330) 
0.0163 
(0.0058, 0.0283) 
Dominant 
 (100%) 
Results for HLA-B*15:02 not reported, and 
not indicated for patients initially presenting 
with gout 
*Based on the probability of the panel being cost-effective for initial use in at least 2 combinations 
‡Dominant means in the south-east quadrant of the cost-effectiveness plane, more effective and less costly 
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Table 3: Input parameters for estimating cost-utility of multiple-gene test 
Allele 
Drug 
Condition 
Incident 
prescriptions 
(per 1000 
population) 
𝜹cost for a single-
gene test 
Mean (SD) 
𝚫QALY for a single-
gene test 
Mean (SD) 
HLA-B*57:01 
Abacavir 
HIV 
0.0940 
[32, 33] 
-£3,148 (£315) b 
[22, 29, 31] 
0.0017 (0.0017) b 
[29] 
HLA-B*58:01 
Allopurinol 
Gout 
0.4301 
[24, 25] 
£49 (£2) c 
[22, 23, 31] 
0.0023 (0.0016) c 
[23] 
HLA-A*31:01a 
Carbamazepine 
Epilepsy 
0.0765 
[26] 
£268 (£74) c 
[21, 22, 31] 
0.0234 (0.0176) c 
[21] 
HLA-B*15:02a 
Carbamazepine & Phenytoin 
Epilepsy 
0.0765 
[22] 
£60d (£6) b 
[22, 28, 31] 
0.0008 (0.00008) b 
[28] 
HLA-B (158T) & HLA-DQB1 
(126Q) 
Clozapine 
Schizophrenia 
0.0370 
[33, 34] 
-£623 (£62) b 
[22, 30, 31] 
-0.0003 (0.00003) b 
[30] 
 
aIn examples where both HLA-A*31:01 and HLA-B*15:02 are included on the panel, 𝛿cost and ΔQALY 
for both genes are combined additively, with a single prevalence in order to reflect the immediate 
relevance of the incidental find 
bAs no published confidence intervals for incremental costs and QALYs, SD assumed as 10% of the 
mean 
cStandard deviations taken from original models [21, 23] 
dTest cost not reported so assumed at £50 ($US65), cost year 2017 
 
